How Many People Are Affected by ALS Today?

Current prevalence: Approximately 16,000 Americans living with ALS in 2026

The National ALS Registry projects approximately 34,720 Americans will be living with ALS in 2026, with men accounting for roughly 17,583 cases and women 14,977. ^[1] These numbers reflect a steady upward trend: from an estimated 32,800 cases in 2022, projections show the total climbing to over 36,300 by 2030 -- a rise of more than 10% over this decade. ^[3] The primary driver is the aging U.S. population, with cases among adults 66 and older expected to jump by 25% between 2022 and 2030. ^[3] Researchers note these figures are likely an underestimate, since emerging therapies and improved care are gradually extending survivability for people living with ALS. ^[2]

Global impact: ALS affects an estimated 400,000 people worldwide

Globally, the number of people living with ALS and related motor neuron diseases climbed from approximately 161,000 in 1990 to 270,000 in 2020, a rise driven primarily by aging populations across both high- and middle-income countries. ^[4] The annual incidence of ALS worldwide falls between 1 and 2.6 new cases per 100,000 people each year, with an overall prevalence of roughly 6 per 100,000. ^[4] Countries with stronger diagnostic infrastructure -- including the United States, which recorded a prevalence of 4.0 per 10,000 in the 2020s -- account for a disproportionate share of reported cases, in part because more patients are identified and tracked. ^[4] In lower-income regions, gaps in specialist access and incomplete disease registries mean the true global count is almost certainly higher than published figures reflect. ^[4]

Why ALS United's clinic finder helps you locate specialized care in your community

Finding a specialized ALS clinic close to home is harder than it should be. Roughly 45 percent of people with ALS in the United States live more than 50 miles from a multidisciplinary care clinic, and only about 40 percent currently receive care at one -- even though multidisciplinary care can reduce one-year mortality by as much as 30 percent.^[5] Our clinic finder addresses this directly, letting you search by location to identify certified ALS centers in your area, including comprehensive centers, regional programs, and affiliated community clinics.^[6] We are here for you, and connecting to the right care team should be one less obstacle on this journey.

What Triggers ALS to Start? Understanding Risk Factors and Incidence Rates

Age and gender statistics: Peak onset between ages 40-60, with men diagnosed 1.5 times more often than women

ALS is rare before age 40, but the risk rises sharply with each decade, with sporadic cases typically starting between ages 58 and 63 and familial ALS tending to appear earlier, between 40 and 60. ^[7] Peak incidence falls in the 70-79 age range. ^[7] Men develop ALS at 1.2 to 1.5 times the rate of women -- a pattern that holds consistently across clinical data and research models, though no single mechanism fully accounts for it. ^[7][8] Recognizing these patterns can help individuals and families identify early symptoms in men before significant progression occurs, particularly when symptoms first emerge during midlife.

Genetic versus sporadic ALS: 10% hereditary cases, 90% non-inherited diagnoses

About 90% of ALS diagnoses are sporadic -- no family history involved -- while roughly 10% are familial, tied to an inherited genetic mutation. ^[9] Among familial cases, approximately 60% carry an identified gene mutation, with C9orf72 accounting for 30-40% of those in the United States and Europe, SOD1 for 15-20% worldwide, and TARDBP for about 5%. ^[10] Even within the sporadic category, some patients carry genetic variants: the C9orf72 expansion appears in 5-10% of people classified as sporadic, suggesting that family history alone doesn't fully capture an individual's genetic risk. ^[9] For families wondering whether ALS could be hereditary, genetic counseling can clarify individual risk, particularly when a close relative has had ALS or a condition like frontotemporal dementia. ^[10]

Environmental and lifestyle risk factors: Military service, occupational exposure, and smoking correlations

Three environmental and lifestyle factors show consistent associations with ALS across multiple studies: military service, occupational exposure to metals and chemicals, and cigarette smoking.

A population-based study in Denmark found military employees had a 30% elevated ALS rate (OR = 1.3), with the highest risk concentrated in the decade immediately after leaving service (OR = 1.6).^[12] Occupational exposure to metals, particulate matter, and volatile organic compounds each raised ALS odds independently, with metals carrying the strongest association in multivariate analysis (OR = 1.48) -- particularly among welders and production workers.^[13] Cigarette smoking also increases risk: people who had ever smoked faced a 70% higher ALS risk (OR = 1.7) in New England data, with odds rising consistently with duration and pack-years -- findings directly relevant to understanding how to prevent ALS in future research.^[11]

ALS Progression and Life Expectancy: What the Data Shows

What is the life expectancy of someone with Lou Gehrig's disease?

Median survival of 2-5 years from diagnosisMost people diagnosed with ALS live 2 to 5 years from the time symptoms begin, with respiratory failure being the most common cause of death.^[14] That range, however, covers wide variation: some people live only a few months, while others survive more than 10 years.^[15] Several factors shape where someone falls within that range, including age at onset, the site where symptoms first appear, and how quickly function declines in the months following diagnosis.^[16] For families trying to plan ahead, understanding ALS life expectancy in more detail -- including the variables that can influence that window -- can help guide care decisions and conversations with the medical team.

Bulbar-onset versus limb-onset: How symptom location affects progression timelines

Where ALS begins in the body directly affects how quickly the disease progresses.

Bulbar-onset ALS -- which first affects speech and swallowing -- carries a shorter median survival than limb-onset; after respiratory involvement, bulbar-onset patients on ventilation face roughly 20% monthly mortality compared to 10% for limb-onset patients. ^[17] Within bulbar-onset cases specifically, how fast limb weakness appears is the strongest predictor of survival: those who develop significant limb weakness within 20 months of bulbar symptoms have a median survival of 26 months, while those who remain predominantly bulbar beyond that point reach a median of 64 months. ^[18] For families navigating this, understanding the distinctions between bulbar ALS and limb-onset ALS can help align care planning with what's actually happening in the body.

Emerging treatment impact: How newer therapies and comprehensive support are extending quality of life

Approved ALS medications offer modest but real benefits: riluzole extends median survival by 2 to 3 months, and edaravone reduced functional decline by approximately 33% in early-stage patients meeting specific eligibility criteria. ^[20] Tofersen, FDA-approved in 2023 for patients with SOD1 gene mutations, reduced a key marker of neuronal damage by approximately 60% compared to placebo -- the first precision-medicine approval in ALS. ^[19] Noninvasive ventilation extends survival by an average of 205 days in clinical trials, and multidisciplinary care combining neurology, nutrition, respiratory therapy, and speech support remains the most broadly accessible tool for preserving function. ^[19] For families navigating a new diagnosis, accessing comprehensive ALS support that integrates pharmacological and practical resources gives people their strongest current foundation for both survival and quality of life.

The Burden on Caregivers: Statistics That Reveal Why Community Support Matters

Caregiver demographics and emotional impact: 80% of caregivers report significant stress and burden

ALS caregivers are typically female partners or adult children with no prior caregiving experience -- a 2026 study of 113 informal caregivers found that 61.9% were women, 65.5% were partners, and 77% were first-time caregivers. ^[21] Caregiver burden averaged 32 out of 88 on the Zarit Burden Interview, with 43.8% reporting mild to moderate levels and 27.7% reporting moderate-to-severe or severe strain -- meaning the majority were experiencing meaningful burden. ^[21] Mental health and vitality scores fell substantially below general population norms, and sleep quality declined significantly after assuming care, with 40.9% experiencing caregiving-related nighttime awakenings on most or all nights. ^[21] Burden grew in direct proportion to caregiving hours and patient disability level, underscoring the importance of connecting with support resources for caregivers and families well before the disease reaches advanced stages. ^[21]

Economic costs of ALS care: Average lifetime costs exceed $250,000 per patient

The financial burden of ALS care is substantial and grows with disease severity.

A cross-sectional study of patients in Germany estimated lifetime costs at approximately 246,184€ per person, with mean annual costs of 78,256€ -- roughly 17 times the country's average per-capita healthcare spending. ^[22] Nearly half of those total costs (46.2%) came from informal caregiving by family members rather than formal medical services, placing a large share of the financial weight directly on households. ^[22] A U.S. case study documented total disease-duration costs of $1,433,992 for one patient over 10 years, with in-home caregivers ($669,150), ventilation ($212,430), and hospital care ($114,558) as the largest cost drivers. ^[23] Understanding insurance options after an ALS diagnosis can help families plan earlier and reduce financial strain at later disease stages.

How ALS United's support services and counseling programs reduce caregiver isolation and improve outcomes

Social isolation is one of the most consistent burdens caregivers describe, and structured peer support directly addresses it.

Research shows that quality of life for people with ALS is shaped more by psychosocial factors -- including perceived social support and coping skills -- than by disease duration or symptom severity alone. ^[24] Online peer support programs offer informational, emotional, and network support, giving caregivers a space to share experiences and develop adaptive coping strategies without needing to travel. ^[24] A qualitative study of neuromuscular disease caregivers found that digital peer support reduced isolation and built a sense of community that family networks alone could not provide. ^[25] Our virtual ALS support groups connect caregivers from home, putting that same layer of support within reach.